vs
Lakeside Holding Ltd（LSH）与Profound Medical Corp.（PROF）财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是Profound Medical Corp.的1.2倍（$7.0M vs $6.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -136.8%，领先114.2%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
康派集团医疗SE & Co. KGaA是一家总部位于德国科布伦茨的上市软件企业，专注于为医疗领域开发并提供相关软件产品，面向诊所、药房、医学实验室与医院推出支持诊疗及运营工作的云化数字应用软件。截至2022年，该公司全球员工规模超9200人，业务覆盖56个国家，拥有超过160万用户。
LSH vs PROF — 直观对比
营收规模更大
LSH
是对方的1.2倍
$6.0M
净利率更高
LSH
高出114.2%
-136.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $6.0M |
| 净利润 | $-1.6M | $-8.2M |
| 毛利率 | 27.2% | 66.8% |
| 营业利润率 | -21.3% | -123.3% |
| 净利率 | -22.6% | -136.8% |
| 营收同比 | 95.0% | — |
| 净利润同比 | 18.7% | — |
| 每股收益（稀释后） | $-0.08 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHPROF
| Q4 25 | $7.0M | $6.0M | ||
| Q3 25 | $6.1M | $5.1M | ||
| Q2 25 | $6.3M | $2.0M | ||
| Q1 25 | $3.8M | $2.3M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.1M | — |
净利润LSHPROF
| Q4 25 | $-1.6M | $-8.2M | ||
| Q3 25 | $-1.4M | $-8.0M | ||
| Q2 25 | $-893.1K | $-15.7M | ||
| Q1 25 | $-1.1M | $-10.7M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-1.3M | — |
毛利率LSHPROF
| Q4 25 | 27.2% | 66.8% | ||
| Q3 25 | 18.2% | 77.7% | ||
| Q2 25 | 26.7% | 81.7% | ||
| Q1 25 | 18.8% | 79.2% | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 12.8% | — |
营业利润率LSHPROF
| Q4 25 | -21.3% | -123.3% | ||
| Q3 25 | -20.8% | -176.2% | ||
| Q2 25 | -8.9% | -696.9% | ||
| Q1 25 | -28.2% | -477.0% | ||
| Q4 24 | -55.6% | — | ||
| Q3 24 | -32.5% | — |
净利率LSHPROF
| Q4 25 | -22.6% | -136.8% | ||
| Q3 25 | -22.2% | -157.7% | ||
| Q2 25 | -14.2% | -792.3% | ||
| Q1 25 | -28.2% | -458.1% | ||
| Q4 24 | -54.1% | — | ||
| Q3 24 | -32.7% | — |
每股收益（稀释后）LSHPROF
| Q4 25 | $-0.08 | $0.27 | ||
| Q3 25 | $-0.09 | $0.26 | ||
| Q2 25 | $-0.11 | $0.52 | ||
| Q1 25 | $-0.14 | $0.36 | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.18 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $59.7M |
| 总债务越低越好 | $2.4M | $4.5M |
| 股东权益账面价值 | $12.2M | $66.4M |
| 总资产 | $24.3M | $77.5M |
| 负债/权益比越低杠杆越低 | 0.20× | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资LSHPROF
| Q4 25 | $1.6M | $59.7M | ||
| Q3 25 | $4.5M | $24.8M | ||
| Q2 25 | $5.0M | $35.2M | ||
| Q1 25 | $1.5M | $46.4M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $2.7M | — |
总债务LSHPROF
| Q4 25 | $2.4M | $4.5M | ||
| Q3 25 | $2.4M | $4.5M | ||
| Q2 25 | $1.4M | $4.5M | ||
| Q1 25 | $774.2K | $4.5M | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — |
股东权益LSHPROF
| Q4 25 | $12.2M | $66.4M | ||
| Q3 25 | $7.0M | $32.1M | ||
| Q2 25 | $2.8M | $39.3M | ||
| Q1 25 | $749.8K | $50.8M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $3.6M | — |
总资产LSHPROF
| Q4 25 | $24.3M | $77.5M | ||
| Q3 25 | $18.6M | $42.3M | ||
| Q2 25 | $14.4M | $49.7M | ||
| Q1 25 | $9.9M | $60.9M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $10.8M | — |
负债/权益比LSHPROF
| Q4 25 | 0.20× | 0.07× | ||
| Q3 25 | 0.35× | 0.14× | ||
| Q2 25 | 0.48× | 0.11× | ||
| Q1 25 | 1.03× | 0.09× | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $-6.6M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LSHPROF
| Q4 25 | $-453.5K | $-6.6M | ||
| Q3 25 | $-4.0M | $-9.6M | ||
| Q2 25 | $-483.7K | $-13.7M | ||
| Q1 25 | $-238.3K | $-8.3M | ||
| Q4 24 | $-530.2K | — | ||
| Q3 24 | $-1.4M | — |
自由现金流LSHPROF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-497.4K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-560.5K | — | ||
| Q3 24 | $-1.4M | — |
自由现金流率LSHPROF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -7.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.6% | — | ||
| Q3 24 | -34.5% | — |
资本支出强度LSHPROF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.1% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
PROF
暂无分部数据
